
|Articles|September 15, 2002
Glaucoma patients experience hyperemia with medications
Two glaucoma drugs approved last year, travoprost (Travatan, Alcon) and bimatoprost (Lumigan, Allergan), are associated with higher rates of hyperemia than the more established drug latanoprost (Xalatan, Pharmacia). However, the hyperemia is seldom a clinically significant side effect, according to a sampling of physicians who are familiar with all three drugs.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Alcon raises offer in amended deal to acquire STAAR Surgical
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
5














































.png)


